12 results about "Human tumor" patented technology

The application discloses a kind of thieno [2, 3-c] pyrazole compounds in preparation antitumor drug purposes, belong to pharmaceutical chemistry technical field.The application provides a kind of small molecule skeleton thieno [2, 3-c] pyrazole compound I and II, compound I is 2-oxo benzo [d] [1, 3] oxathiole-6-yl 1-(3-fluorophenyl)-3-methyl-1H-thieno [2, 3-c] pyrazole-5-carboxylate.Compound II is 1-(4-chlorophenyl)-N-[4-((4-ethylpiperazine-1-yl)methyl)phenyl]-3-methyl-1H-thieno [2, 3-c] pyrazole-5-formyl.Both have strong antitumor activity.Compound II has strong inhibition to a variety of human tumor cells, such as bone sarcoma MG63, breast cancer HCC1806, liver cancer LM3, lung cancer A549, colorectal cancer HCT-8 and the like, provides new candidate compounds for broad-spectrum antitumor drugs.

The purpose of the present disclosure is to develop a new combination therapy that exerts a superior antitumor effect as compared to administration of an anti-CD26 antibody alone. In order to assess both the function of an immune checkpoint inhibitor and the antitumor effect of an anti-CD26 antibody, it is necessary to be provided with both a binding site on a human CD26 molecule and an immune system of the same lineage of a cancer cell. Thus, in order to acquire data of an immune checkpoint inhibitor and an anti-CD26 antibody, it is essential to perform analysis in a human immune system and a human tumor cell line. The present inventors have made an attempt to produce a human immune system mouse to be used as a model animal for confirming the effect of the combination between ICI and an anti-CD26 antibody, and have successfully produced a model mouse superior for generating human T-cells. Next, the present inventors have studied the effect of combining an immune checkpoint inhibitor and an anti-CD26 antibody in a tumor bearing model by using said mouse. As a result, it was found that an agent using said combination has a synergistic effect that is stronger than when the respective agents are used individually.

A NOD.Cg-Prkdcscid NSG) mouse which is genetically modified such that the NSG mouse lacks functional major histocompatibility complex I (MHC I) and lacks functional major histocompatibility complex II (MHC II) is provided according to aspects of the present invention. According to specific aspects the genetically modified NSG mouse is a NOD.Cg- Prkdcscid H2-K1tml Bpe H2-Ab1em Mvw H2-D1tml H2rg Wjl / SzJ NSG- RIP-DTR (IAnull) mouse, or a NOD.Cg-B2m'm" Une Prkdcscid H2dlAbl-Ea H2rg!"1 Wjl / SzJ (NSG- B2M ull (IA mouse. Human immune cells and / or human tumor cells are administered to a genetically modified immunodeficient mouse according to aspects described herein and assays of one or more test substances can be performed using the provided mice. 20 24 20 47 25 09 J ul 2 02 4 A B S T R A C T 2 0 2 4 2 0 4 7 2 5 0 9 J u l 2 0 2 4

The invention provides an mRNA (messenger Ribonucleic Acid) medicine for inhibiting tumor stem cells and reducing the dryness of the tumor cells and a preparation method of the mRNA medicine. The mRNA medicine comprises any one or a combination of at least two of linear PTEN mRNA, self-replicating PTEN mRNA and annular PTEN mRNA; the linear PTEN mRNA comprises a 5 'UTR (Untranslated Region) sequence, a PTEN protein coding sequence and a 3' UTR sequence; the nucleotide sequence of the PTEN protein coding sequence comprises a sequence as shown in SEQ ID NO. 1. The mRNA nano-drug prepared by the invention not only has high transfection efficiency in tumor stem cells, but also can induce differentiation of the tumor stem cells and remarkably inhibit growth of the tumor stem cells; in drug-resistant tumor cells, the stemness of the drug-resistant tumor cells is inhibited, so that the sensitivity to chemotherapy, targeted antibodies, immunotherapy and the like is improved, and the killing effect of the drug is improved. The invention also shows an excellent anti-tumor effect in a human tumor cell line xenotransplantation model of the drug-resistant breast cancer in vivo, and provides a promising treatment strategy for the treatment of the drug-resistant breast cancer.

Provided are a vector genetically engineered with a chimeric antigen receptor and against two or more targets for combined treatment of disease such as human tumors, a related immune cell and application thereof. The vector genetically engineered with a chimeric antigen receptor and the related immune cell have enhanced ability to kill target cells.

The application belongs to the field of medicine, and particularly relates to application of a benzothiazepine compound in preparation of a cancer treatment drug, wherein the benzothiazepine compound has a structural formula as shown in formula I, and the cancer is at least one selected from liver cancer, intestinal cancer, bone cancer and lung cancer. According to a cell activity experiment of the application, it is found that the compound shown in formula I shows clear and different activities on human liver cancer cells, human lung cancer cells, human osteosarcoma cells and human colorectal cancer cells in vitro. The inventors of the application find, for the first time, through activity screening on a small molecule skeleton, that the benzothiazepine compound shown in formula I has excellent activity on various different types of human tumors, and the benzothiazepine compound provides an optional scheme for a broad-spectrum anticancer drug.

The application discloses application of sulfonamide pyrrole compounds in preparation of anticancer drugs and belongs to the technical field of medicinal chemistry. The application provides a kind of sulfonamide pyrrole small molecule compounds with broad-spectrum antitumor potential: compound I and compound II. In vitro pharmacological experiment results show that compound I and compound II are all significantly active in inhibiting the proliferation of various human tumor cell lines such as breast cancer HCC1806, osteosarcoma MG63, colorectal cancer HCT-8, liver cancer LM3 and lung cancer A549, and the inhibitory effect is concentration-dependent. The above results show that the sulfonamide pyrrole compounds have good application prospect in the development of antitumor drugs and can be used as candidate molecules for developing new broad-spectrum antitumor drugs.

The application discloses a cell communication prediction method and application based on Boosting, deep forest and single-cell sequencing data, and is characterized in that: on the basis of extracting ligand and receptor biological characteristics, a limit gradient boosting algorithm is designed to select the characteristics of ligand-receptor pairs; then, based on a category characteristic gradient boosting algorithm, a natural gradient boosting algorithm and a deep forest model, an integrated framework is designed to predict ligand-receptor interaction; and combined with single-cell sequencing data of tumor tissues, known and predicted ligand-receptor interaction data are filtered; and then, according to the filtered ligand-receptor interaction and single-cell sequencing data, combined with an expression product method and an expression threshold method, cell communication in a tumor microenvironment is predicted. The method can improve the prediction effect of cell communication, can be applied to cell communication prediction in human tumor tissues, and solves the problem that the accuracy of predicting cell communication intensity based on ligand-receptor interaction in the prior art is not high.

This invention proposes a method for culturing human tumor organoids based on green light volumetric bioprinting (GLVBP) technology, belonging to the field of bioculture technology. By optimizing the bio-ink formulation, this invention combines human tumor cells with photocrosslinked biomaterials (such as methacrylated gelatin and hyaluronic acid derivatives) and a matrix adhesive to prepare a photocurable bio-ink suitable for GLVBP. Using GLVBP technology, three-dimensional models of tumor organoids with biomimetic structures can be rapidly constructed, achieving efficient proliferation and functional maintenance of the organoids. This invention solves the problems of poor structural controllability and large batch-to-batch variability in traditional organoid culture. The prepared tumor organoids possess a highly biomimetic tumor microenvironment and stable biological characteristics, and have significant application value in drug screening, personalized medicine, and tumor mechanism research.